Revenues from Pall’s biopharmaceuticals division grew in fiscal 2009, excluding foreign currency changes, with the company benefiting from the “thriving market” for vaccines and expanding adoption of single-use systems.
Pall seems to have shaken off the financial turmoil of recent
months in the second quarter of 2008, with a 15 per cent hike in
sales to $626m helped by favourable dollar exchange rates and a
strong performance by its biopharmaceuticals...
As single-use technologies become more and more popular for use in
biopharmaceutical manufacturing, Pall is following market demands
bolstering its product line by adding a number of disposable
products to its portfolio.